세계의 코미르나티(토지나멜란) 시장 보고서(2025년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Comirnaty (Tozinameran) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

US $ 4,490 ￦ 6,675,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,648,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,622,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

코미르나티(토지나멜란) 시장 규모는 향후 몇 년간 급속한 성장을 기록할 것으로 예상됩니다. 예측 기간의 성장은 소아용 사용 승인, 변이 바이러스에 특화된 백신에 대한 수요, 저소득 지역의 백신 접근성 향상, 민간 부문의 백신 조달 증가, mRNA 기술의 새로운 치료 응용 분야 등 여러 요인에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 mRNA 플랫폼 혁신에 대한 관심 증가, AI 기반 분석과 백신 생산의 통합, 차세대 백신의 경쟁 심화, 백신 생산의 지속 가능성에 대한 관심, 바늘이 필요 없는 백신 투여 방법의 발전 등이 있습니다.

감염병의 유행이 증가함에 따라 코미르나티(토지나멜란) 시장의 성장이 크게 촉진될 것으로 예상됩니다. 박테리아, 바이러스, 곰팡이, 기생충과 같은 병원균에 의해 발생하는 감염병은 전 세계 여행, 도시화, 기후 변화, 부적절한 의료 서비스 이용 등 여러 요인의 영향으로 더욱 확산되고 있습니다. 코미르나티(토지나멜란)는 mRNA 기술을 활용하여 효과적인 보호를 제공함으로써 전염병, 특히 COVID-19를 통제하는 데 중요한 역할을 합니다. 이 약물은 전염률을 감소시키고, 중증 사례를 예방하며, 입원 건수를 최소화하는 데 도움이 됩니다. 예를 들어, 영국 보건 보안청(UK Health Security Agency)은 2023년에 홍역 사례가 약 7배 증가했다고 보고했으며, 이는 전염병에 대항하기 위해 코미르나티와 같은 효과적인 백신의 필요성이 증가하고 있음을 강조합니다. 그 결과, 전염병의 유행이 증가하면서 코미르나티에 대한 수요가 촉진되고 있습니다.

맞춤형 의약품의 증가 추세는 코미르나티 시장의 성장을 촉진할 것으로 예상됩니다. 맞춤형 의약품은 유전적 구성, 생활 방식, 환경 등 개인의 특성에 따라 치료를 맞춤화하여 치료 결과를 개선합니다. 이러한 접근 방식은 유전학, 정밀 진단 기술의 발전과 더 표적화된 치료법에 대한 수요로 인해 성장하고 있습니다. mRNA 기술을 갖춘 코미르나티는 개별 유전적 특성에 빠르게 적응할 수 있는 유연한 백신 플랫폼을 제공하여 이러한 동향을 지원합니다. 2022년에 FDA는 신약의 34%에 대해 맞춤형 의약품을 승인하여 맞춤형 의약품의 채택이 증가하고 있음을 강조했습니다. 따라서 맞춤형 의약품의 부상은 코미르나티 시장의 성장을 더욱 촉진할 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장에서의 제품 특성

• 분자 유형
• 투여경로(ROA)
• 작용기전(MOA)
• 안전성과 유효성

제4장 시장 동향과 전략

제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 코미르나티(토지나멜란) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 코미르나티(토지나멜란) 시장 : 성장률 분석
• 세계의 코미르나티(토지나멜란) 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 코미르나티(토지나멜란) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 코미르나티(토지나멜란) : 전체 시장 규모(TAM)

제7장 세계 시장의 가격 분석과 예측

제8장 시장 세분화

• 세계의 코미르나티(토지나멜란) 시장 : 배합별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 기존
• 지질 나노입자
• 기타
• 세계의 코미르나티(토지나멜란) 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• COVID-19 예방
• COVID-19 치료
• 세계의 코미르나티(토지나멜란) 시장 : 작용기전별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 스파이크 단백질 코딩 mRNA
• 중요성분 코딩 mRNA
• 세계의 코미르나티(토지나멜란) 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 클리닉
• 기타
• 세계의 코미르나티(토지나멜란) 시장 : 대상 인구별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 성인
• 유아(12세 이상)
• 유아(12세)

제9장 임상적응증 세계 시장 역학

• 약제의 부작용
• 임상적응증의 발병률과 유병률

제10장 지역별, 국가별 분석

• 세계의 코미르나티(토지나멜란) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 코미르나티(토지나멜란) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도와 기업 프로파일

• 코미르나티(토지나멜란) 시장 : 경쟁 구도
• 코미르나티(토지나멜란) 시장 : 기업 프로파일
  • Pfizer Inc.
  • BioNTech SE

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 전략

• 코미르나티(토지나멜란) 시장(2029년) : 새로운 기회를 제공하는 국가
• 코미르나티(토지나멜란) 시장(2029년) : 새로운 기회를 제공하는 부문
• 코미르나티(토지나멜란) 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제34장 부록

HBR

영문 목차

영문목차

Comirnaty (tozinameran) is an mRNA-based vaccine developed for the prevention of COVID-19. It uses lipid nanoparticles to deliver mRNA, instructing cells to produce a protein resembling the SARS-CoV-2 spike protein, which triggers an immune response. This helps prevent COVID-19 infection and reduces the severity of the disease, including severe outcomes like hospitalization and death.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main formulations for comirnaty include conventional and lipid nanoparticle-based formats, designed to enhance the delivery and efficacy of the vaccine. The primary indications for this vaccine are COVID-19 prevention and treatment. Comirnaty works by utilizing mRNA that encodes for the spike protein and other key viral components, enabling a precise immune response. It is used in various healthcare settings, including hospitals and clinics, and is intended for adults, children aged 12 and older, and, in some cases, children under 12, ensuring broad accessibility for diverse age groups.

The comirnaty (tozinameran) market research report is one of a series of new reports from The Business Research Company that provides comirnaty (tozinameran) market statistics, including comirnaty (tozinameran) industry global market size, regional shares, competitors with a comirnaty (tozinameran) market share, detailed comirnaty (tozinameran) market segments, market trends and opportunities, and any further data you may need to thrive in the comirnaty (tozinameran) industry. This comirnaty (tozinameran) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The comirnaty (tozinameran) market size is expected to see exponential growth in the next few years. It will grow to $17,976.3 million in 2029 at a compound annual growth rate (CAGR) of 21%. The growth in the forecast period can be attributed to authorization for pediatric use, demand for variant-specific vaccines, increased vaccine accessibility in low-income regions, increasing private sector vaccine procurement, and emerging therapeutic applications of mRNA technology. Major trends in the forecast period include growing focus on mRNA platform innovations, integration of vaccine production with AI-driven analytics, increasing competition from next-generation vaccines, focus on sustainability in vaccine production, and advancements in needle-free vaccine delivery methods.

The increasing prevalence of infectious diseases is expected to significantly drive the growth of the comirnaty (tozinameran) market. Infectious diseases, caused by pathogens like bacteria, viruses, fungi, or parasites, are spreading more due to factors such as global travel, urbanization, climate change, and inadequate healthcare access. Comirnaty (tozinameran) plays a crucial role in controlling infectious diseases, especially COVID-19, by leveraging mRNA technology to provide effective protection. It helps reduce transmission rates, prevent severe cases, and minimize hospitalizations. For instance, the UK Health Security Agency reported a nearly sevenfold increase in measles cases in 2023, which highlights the growing need for effective vaccines like Comirnaty to combat infectious diseases. As a result, the rising prevalence of infectious diseases is driving the demand for comirnaty.

Rising trends in personalized medicine are expected to propel the growth of the comirnaty market. Personalized medicine tailors treatments based on individual characteristics such as genetic makeup, lifestyle, and environment to improve treatment outcomes. This approach is growing due to advancements in genomics, precision diagnostics, and the demand for more targeted therapies. Comirnaty, with its mRNA technology, supports this trend by providing a flexible vaccine platform that can be rapidly adapted to meet individual genetic profiles. In 2022, the FDA approved personalized medicines for 34% of new drugs, underscoring the increasing adoption of personalized medicine. Thus, the rise of personalized medicine will further fuel the growth of the comirnaty market.

A key trend in the comirnaty market is the development of innovative products such as the bivalent mRNA COVID-19 vaccine, which provides enhanced protection against both the original virus and emerging variants like Omicron. Bivalent vaccines are designed to target both the original SARS-CoV-2 strain and specific variants, improving immune response and offering broader protection. In December 2023, the Therapeutic Goods Administration in Australia approved Pfizer's COMIRNATY Original/Omicron BA.4-5 COVID-19 Vaccine as a booster for individuals aged 5 years and older. This approval reflects the growing trend of adapting vaccines to target evolving strains, ensuring continued effectiveness against emerging COVID-19 variants and strengthening global public health resilience.

Major players operating in the comirnaty (tozinameran) market are Pfizer Inc.; BioNTech SE

North America was the largest region in the comirnaty (tozinameran) market in 2024. The regions covered in comirnaty (tozinameran) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the comirnaty (tozinameran) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The comirnaty (tozinameran) market consists of sales of multidose vials, single-dose prefilled syringes, and combination products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Comirnaty (Tozinameran) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on comirnaty (tozinameran) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for comirnaty (tozinameran) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The comirnaty (tozinameran) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Formulation: Conventional; Lipid Nanoparticles; Other Formulations
• 2) By Indication: COVID-19 Prevention; COVID-19 Treatment
• 3) By Mechanism Of Action: mRNA Coding For Spike Protein; mRNA Coding For Vital Components
• 4) By Application: Hospital; Clinic; Other
• 5) By Intended Population: Adults; Children (>=12 Years); Children (12 Years)
• Companies Mentioned: Pfizer Inc.; BioNTech SE
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Comirnaty (Tozinameran) Market Characteristics

3. Comirnaty (Tozinameran) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Comirnaty (Tozinameran) Market Trends And Strategies

5. Comirnaty (Tozinameran) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Comirnaty (Tozinameran) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Comirnaty (Tozinameran) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Comirnaty (Tozinameran) Market Growth Rate Analysis
• 6.4. Global Comirnaty (Tozinameran) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Comirnaty (Tozinameran) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Comirnaty (Tozinameran) Total Addressable Market (TAM)

7. Global Comirnaty (Tozinameran) Market Pricing Analysis & Forecasts

8. Comirnaty (Tozinameran) Market Segmentation

• 8.1. Global Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional
• Lipid Nanoparticales
• Other Formulations
• 8.2. Global Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• COVID-19 Prevention
• COVID-19 Treatment
• 8.3. Global Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• mRNA Coding For Spike Protein
• mRNA Coding For Vital Components
• 8.4. Global Comirnaty (Tozinameran) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic
• Other Applications
• 8.5. Global Comirnaty (Tozinameran) Market, Segmentation By Intended Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adults
• Children (>=12 Years)
• Children (12 Years)

9. Global Comirnaty (Tozinameran) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Comirnaty (Tozinameran) Market Regional And Country Analysis

• 10.1. Global Comirnaty (Tozinameran) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Comirnaty (Tozinameran) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Comirnaty (Tozinameran) Market

• 11.1. Asia-Pacific Comirnaty (Tozinameran) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Comirnaty (Tozinameran) Market

• 12.1. China Comirnaty (Tozinameran) Market Overview
• 12.2. China Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Comirnaty (Tozinameran) Market

• 13.1. India Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Comirnaty (Tozinameran) Market

• 14.1. Japan Comirnaty (Tozinameran) Market Overview
• 14.2. Japan Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Comirnaty (Tozinameran) Market

• 15.1. Australia Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Comirnaty (Tozinameran) Market

• 16.1. South Korea Comirnaty (Tozinameran) Market Overview
• 16.2. South Korea Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Comirnaty (Tozinameran) Market

• 17.1. Western Europe Comirnaty (Tozinameran) Market Overview
• 17.2. Western Europe Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Comirnaty (Tozinameran) Market

• 18.1. UK Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Comirnaty (Tozinameran) Market

• 19.1. Germany Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Comirnaty (Tozinameran) Market

• 20.1. France Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Comirnaty (Tozinameran) Market

• 21.1. Eastern Europe Comirnaty (Tozinameran) Market Overview
• 21.2. Eastern Europe Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Comirnaty (Tozinameran) Market

• 22.1. North America Comirnaty (Tozinameran) Market Overview
• 22.2. North America Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Comirnaty (Tozinameran) Market

• 23.1. USA Comirnaty (Tozinameran) Market Overview
• 23.2. USA Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Comirnaty (Tozinameran) Market

• 24.1. Canada Comirnaty (Tozinameran) Market Overview
• 24.2. Canada Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Comirnaty (Tozinameran) Market

• 25.1. South America Comirnaty (Tozinameran) Market Overview
• 25.2. South America Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Comirnaty (Tozinameran) Market

• 26.1. Middle East Comirnaty (Tozinameran) Market Overview
• 26.2. Middle East Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Comirnaty (Tozinameran) Market

• 27.1. Africa Comirnaty (Tozinameran) Market Overview
• 27.2. Africa Comirnaty (Tozinameran) Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Comirnaty (Tozinameran) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Comirnaty (Tozinameran) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Comirnaty (Tozinameran) Market Competitive Landscape And Company Profiles

• 28.1. Comirnaty (Tozinameran) Market Competitive Landscape
• 28.2. Comirnaty (Tozinameran) Market Company Profiles
  • 28.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. BioNTech SE Overview, Products and Services, Strategy and Financial Analysis

29. Global Comirnaty (Tozinameran) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Comirnaty (Tozinameran) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Comirnaty (Tozinameran) Market

32. Recent Developments In The Comirnaty (Tozinameran) Market

33. Comirnaty (Tozinameran) Market High Potential Countries, Segments and Strategies

• 33.1 Comirnaty (Tozinameran) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Comirnaty (Tozinameran) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Comirnaty (Tozinameran) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer

관련자료